Iron deficiency in cancer patients;Deficiência de ferro no paciente com câncer

Revista Brasileira de Hematologia e Hemoterapia

Volumn 32, Issue SUPPL. 2, 2010, Pages 95-98

  Calabrich, Aknar F C ^a   Katz, Artur ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

Anemia; Cancer; Iron

Indexed keywords

EID: 78649540473     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-84842010005000049     Document Type: Review

References (26)

1. Bokemeyer C, Foubert J. Anemia impact and management: focus on patient needs and the use of erythropoietic agents. Seminars in oncology. 2004;31(3 Suppl 8):4-11.
2. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-306.
3. Ludwing H, Aapro M, Bokemeyer C, Macdonald K, Soubeyran P, Turner M, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer. 2009 Mar 9: Epub ahead of print.
4. Henry DH, Dahl NV. Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy. Commun Oncol. 2007;4:95-101.
5. Goodman D, Irvin TT. Delay in the diagnosis and prognosis of carcinoma of the right colon. Br J Surg. 1993;80(10):1327-9.
6. Theurl I, Mattle V, Seifert M, Mariani M, Marth C, Weiss G. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood. 2006; 107(10):4142-8.
7. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783-8.
8. Truksa J, Peng H, Lee P, Beutler E. Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol. 2007;139(1): 138-47.
9. Chen YM, Whang-Peng J, Liu JM, Kuo BI, Wang SY, Tsai CM, et al. Serum cytokine level fluctuations in chemotherapy-induced myelosuppression.Jpn J Clin Oncol. 1996;26(1):18-23.
10. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol. 2001;28(2 Suppl 8):7-14.
11. Pujade-Lauraine E, Gascon P. The burden of anaemia in patients with cancer. Oncology. 2004;67(Suppl 1):1-4.
12. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63-74.
13. Holzner B, Kemmler G, Greil R, Kopp M, Zeimet A, Raderer M, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol. 2002;13(6):965-73.
14. Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N, et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer. 2002;86(8): 1243-9.
15. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000;11(8):971-5.
16. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology. 1996;201(2):553-8.
17. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998;48(2):149-56.
18. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91(12):2214-21.
19. Hedenus M, Birgegard G. The role of iron supplementation during epoietin treatment for cancer-related anemia. Med Oncol. 2009; 26(1):105-15.
20. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22(7):1301-7.
21. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12 (2):231-42.
22. Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26(10):1611-8.
23. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008;26(10):1619-25.
24. Auerbach M, Silberstein T, Webb T, Averyanova S, Ciuleanu T, Cam L, et al. Darbepoetin alfa (da) 500mcg or 300mcg once every three weeks (q3w) with or without iron in patients (pts) with chemotherapy-induced anemia (CIA). Ann Oncol. 2008;19 (suppl 8):viii1-viii4.
25. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Cancer-and Chemotheraopy-Induced Anemia. Version 3.2009. Available at: http://www.nccn.org.
26. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008;111(1):25-41.